Valuation: StimCell Energetics Inc.

Market Cap 5.83M 5.1M 4.71M 4.36M 8.27M 557M 8.4M 56.37M 22.1M 274M 21.91M 21.43M 947M P/E 2026 *
-6.9x
P/E 2027 * -13.8x
Enterprise Value 6.63M 5.8M 5.35M 4.95M 9.4M 633M 9.56M 64.1M 25.13M 311M 24.91M 24.37M 1.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
28.33%
Yield 2026 *
-
Yield 2027 * -
1 day-12.10%
1 week-12.10%
Current month-12.10%
1 month-20.89%
3 months-21.14%
6 months-42.14%
Current year-31.00%
1 week 0.28
Extreme 0.276
0.28
1 month 0.28
Extreme 0.276
0.35
Current year 0.28
Extreme 0.276
0.48
1 year 0.25
Extreme 0.2501
0.48
3 years 0
Extreme 0.0015
13.97
5 years 0
Extreme 0
13.97
10 years 0
Extreme 0
25.35
Manager TitleAgeSince
Chief Executive Officer 56 11/12/2023
Director of Finance/CFO 48 23/11/2014
Director TitleAgeSince
Chairman 78 25/02/2024
Director/Board Member 62 07/06/2020
Director/Board Member 56 11/12/2023
Date Insider Type Main position Quantity % Market Cap.
12-17Sell

Director

16,667 0.0807%
16/03/25Tax

Director

60,841,472 307.0278%
24/02/25Buy 15,000 0.0757%
Change 5-day change 1-year change 3-year change Capi.($)
-12.10%-12.10%-37.27%+15.00% 5.83M
+1.18%+2.23%+3.09%+11.05% 50.44B
+0.72%+1.00%+396.18%+624.25% 40.63B
+2.54%+0.93%+28.98%-3.62% 34.88B
+0.31%+1.74%+18.44%+59.76% 33.67B
-2.09%-1.98%+3.21%+33.56% 26.29B
-0.63%+0.34% - - 17.11B
+0.66%-3.96%+66.85%+127.36% 15.29B
-23.90%-21.43%+50.06%+53.83% 10.62B
+1.19%+0.12%+14.55%+21.95% 13.74B
Average -3.22%-2.44%+60.45%+104.79% 24.27B
Weighted average by Cap. -0.42%-0.61%+87.44%+139.70%

Financials

2026 *2027 *
Net sales - -
Net income -792M -693M -639M -591M -1.12B -75.64B -1.14B -7.66B -3B -37.14B -2.97B -2.91B -129B -510M -446M -411M -381M -723M -48.68B -735M -4.93B -1.93B -23.91B -1.91B -1.87B -82.81B
Net Debt 800K 700K 645K 597K 1.13M 76.36M 1.15M 7.73M 3.03M 37.5M 3M 2.94M 130M 800K 700K 645K 597K 1.13M 76.36M 1.15M 7.73M 3.03M 37.5M 3M 2.94M 130M
Logo StimCell Energetics Inc.
StimCell Energetics Inc. is a biotech company, which is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System. eBalance is a non-invasive, fully automated microcurrent electrotherapy system administering pre-programmed algorithms through the epidermis at the touch of a button to help you gain optimal wellness and reduce pain. Its eBalance represents a monumental stride in the realm of medical technology designed to rejuvenate and re-energize the human body at a cellular level. The operation of eBalance is an intricate process of precision engineering and human biology.
Employees
1
Date Price Change Volume

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STME Stock